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Familial cerebral cavernous malformations 
(CCMs) disease results from autosomal dominant 
loss of function mutations in the genes KRIT1 
(CCM1), CCM2 (malcavernin, MGC4607), 
or PDCD10 (CCM3; Plummer et al., 2005). 
Homozygous null mutations are embryonic 
lethal, whereas heterozygosity predisposes to 
development of CCM lesions (Sahoo et al., 
1999; Liquori et al., 2003); however, lesions 
may also arise sporadically. CCM lesions are 
dilated clusters of small vessels composed 
of fragile endothelium lacking underlying 
smooth muscle, with altered subendothelial 
extracellular matrix and no intervening neural 
parenchyma. Cerebral lesions exhibit defec-
tive endothelial cell–cell junctions and cause 
neurological deficits, seizures, and hemor-
rhagic stroke (Awad, 2005). Although some 
CCM patients also develop retinal and epider-
mal lesions, additional in vivo human pheno-
types associated with heterozygosity have not 
been described, except for a description of 
abnormal growths in mesenchymal tissues 
(Ardeshiri et al., 2008).
CCM proteins are expressed in most tis-
sues, including microvascular endothelium, 
but their intracellular functions are still not 
well characterized. We previously found that 
KRIT1 protein is localized to endothelial cell–
cell junctions (Glading et al., 2007) and inter-
acts with the membrane protein Heg1 (heart of 
glass 1; Kleaveland et al., 2009). Small interfer-
ing RNA (siRNA)–mediated depletion of 
KRIT1 led to junction disassembly and loss of 
-catenin from the junctions, which is associated 
with increased monolayer permeability (Glading 
et al., 2007). KRIT1, CCM2, and CCM3 pro-
teins physically interact (Zawistowski et al., 
2005; Hilder et al., 2007a; Voss et al., 2007), 
which, in addition to their genetic relationship, 
suggests that Heg1 and these three proteins 
form a critical node in a signaling pathway reg-
ulating vascular development and endothelial 
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Endothelial cell–cell junctions regulate vascular permeability, vasculogenesis, and angiogen-
esis. Familial cerebral cavernous malformations (CCMs) in humans result from mutations of 
CCM2 (malcavernin, OSM, MGC4607), PDCD10 (CCM3), or KRIT1 (CCM1), a Rap1 effector 
which stabilizes endothelial cell–cell junctions. Homozygous loss of KRIT1 or CCM2  
produces lethal vascular phenotypes in mice and zebrafish. We report that the physical  
interaction of KRIT1 and CCM2 proteins is required for endothelial cell–cell junctional 
localization, and lack of either protein destabilizes barrier function by sustaining activity of 
RhoA and its effector Rho kinase (ROCK). Protein haploinsufficient Krit1+/ or Ccm2+/ 
mouse endothelial cells manifested increased monolayer permeability in vitro, and both 
Krit1+/ and Ccm2+/ mice exhibited increased vascular leak in vivo, reversible by fasudil, a 
ROCK inhibitor. Furthermore, we show that ROCK hyperactivity occurs in sporadic and 
familial human CCM endothelium as judged by increased phosphorylation of myosin light 
chain. These data establish that KRIT1–CCM2 interaction regulates vascular barrier  
function by suppressing Rho/ROCK signaling and that this pathway is dysregulated in 
human CCM endothelium, and they suggest that fasudil could ameliorate both CCM  
disease and vascular leak.
© 2010 Stockton et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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activity, we stained KRIT1 siRNA-treated HUVEC for 
pMLC and evaluated stress fiber content (Fig. 1 C). KRIT1-
depleted cells manifested increased pMLC staining, particu-
larly at cell–cell junctions and along stress fibers, which were 
increased in number. Both effects of KRIT1 siRNA were 
reversed by a ROCK inhibitor, H-1152, and by a second 
ROCK inhibitor, Y27632 (Fig. S1). Staining for phosphory-
lation of a second ROCK substrate, myosin phosphatase 
binding subunit, produced similar results (Fig. S1). Western 
blotting for KRIT1 protein verified the degree of KRIT1 
depletion by siRNA (Fig. 1, B and D). Inhibition of ROCK 
had no effect on the degree of KRIT1 depletion. Of greater 
significance, ROCK inhibition by H-1152 reversed effects of 
KRIT1 depletion on monolayer permeability in HUVEC 
(Fig. 1 E). Thus, suppression of RhoA activity and its down-
stream effector ROCK enables KRIT1 to maintain stability 
of endothelial cell junctions.
KRIT1 haploinsufficiency induces ROCK-mediated vascular leak
KRIT1+/ humans are at risk of developing CCMs, lesions 
which have defective endothelial cell–cell junctions. We found 
that Krit1+/ mice expressed half the WT levels of KRIT1 pro-
tein in pulmonary and brain lysates (Fig. 2, A and B). Krit1+/ 
mice exhibited increased basal vascular leak, as measured by 
Evan’s blue dye extravasation, and greater LPS-induced leak in 
both brain and pulmonary vessels (Fig. 2, C and D). Similar dif-
ferences between WT and heterozygous mice were observed in 
brain and lung edema assays of wet/dry weight, a secondary 
index of vascular leak (Fig. 2, E and F; Wilson et al., 2007). We 
tested brain and lung because both are highly vascular. Although 
clinically recognized CCM lesions are largely cerebral (Gault 
et al., 2006), these data suggest that Krit1+/ mice suffer from 
more widespread vascular endothelial defects. This idea was 
supported by increased pMLC content of endothelial cells 
isolated from multiple organs of Krit1+/ mice (Fig. 3 A). 
Furthermore, KRIT1 protein was expressed at similar levels 
in endothelial cells from all organs evaluated, with endothe-
lial cells from heterozygous mice expressing one-half as much 
as those from WT mice (Fig. 3 A and Fig. S2). Increased 
pMLC staining, actin stress fibers, and monolayer permeabil-
ity were seen in pulmonary endothelial cells cultured from 
Krit+/ mice (Fig. 3, B and C). Thus, hemizygous deficiency 
of KRIT1 leads to haploinsufficiency and generalized vascu-
lar barrier dysfunction, which is reversible by a ROCK 
inhibitor in vivo and in vitro.
KRIT1 or CCM2 deficiency is associated with increased 
pMLC in human cerebral CCM lesions
KRIT1 hemizygosity in humans is associated with development 
of dilated capillary clusters with fragile endothelium, which are 
known to have defective cell–cell junctions and propensity to 
leak (Clatterbuck et al., 2001; Gault et al., 2006). Our findings 
led us to evaluate resected human CCM lesions by immunohis-
tochemistry for increased pMLC as an index of ROCK activity. 
Familial and sporadic cerebral lesions were stained for KRIT1 
and CCM2 to evaluate protein expression. Absence of protein 
permeability. Moreover, these proteins interact with a vari-
ety of other potential signaling molecules. For example, 
KRIT1 binds to and is regulated by Rap1 (Serebriiskii 
et al., 1997; Glading et al., 2007), a known stabilizer of en-
dothelial cell–cell junctions (Cullere et al., 2005; Kooistra 
et al., 2005; Wittchen et al., 2005). The mechanism whereby 
this CCM protein complex regulates vascular functions 
is undefined.
We previously showed that KRIT1 knockdown in 
endothelial cells increases actin stress fibers, a morphology 
which led us to suggest that KRIT1 might suppress RhoA 
signaling, limiting actin-mediated contractility which con-
tributes to endothelial junctional instability. In this paper, 
we report that both KRIT1 and CCM2 are negative regula-
tors of RhoA and its effector Rho kinase (ROCK), thus 
limiting endothelial permeability in vitro and vascular leak. 
Pharmacological blockade of ROCK reversed both KRIT1 
and CCM2 depletion-induced myosin light chain (MLC) 
phosphorylation, actin stress fiber formation, and endothelial 
monolayer permeability in vitro. In vivo, heterozygous 
Krit1+/ and Ccm2+/ mice, deficient in their respective en-
coded proteins, exhibited impaired pulmonary and cerebral 
vessel barrier function that was reversible by treatment with 
the ROCK inhibitor fasudil. Furthermore, isolated endo-
thelium from multiple organs of both Krit1+/ and Ccm2+/ 
mice exhibited increased phosphorylated MLC (pMLC) and 
actin stress fiber content. Both sporadic and familial human 
CCM cerebral lesions displayed increased endothelial MLC 
phosphorylation, indicating that dysregulation of vascular 
RhoA-ROCK signaling is a feature of the human disease. 
Thus, KRIT1 and CCM2 regulate endothelial junctional sta-
bility and vascular barrier function by suppressing activation 
of the RhoA→ROCK pathway. This pathway is hyperacti-
vated in human CCM endothelium and may contribute to 
lesion pathogenesis.
RESULTS
KRIT1 inhibition of RhoA and ROCK maintains endothelial 
barrier function
We previously showed that loss of KRIT1 leads to increased 
endothelial permeability associated with appearance of prom-
inent stress fibers. Stress fiber development is often linked to 
increased RhoA activity (Sun et al., 2006). KRIT1 depletion 
by siRNA caused a 3.5-fold increase in activated RhoA in 
cultured human umbilical vein endothelial cells (HUVECs; 
Fig. 1 A). The specificity of KRIT1 siRNA effect was con-
firmed by transfection with control siRNA and reconstitu-
tion with siRNA-resistant KRIT1. Total RhoA expression 
was unchanged in all conditions (Fig. 1 B). Thus, endoge-
nous endothelial KRIT1 inhibits RhoA activity.
ROCK is a RhoA effector mediating actin stress fiber 
formation in part by increasing MLC phosphorylation 
and, consequently, cellular contractility. MLC is a ROCK 
substrate. ROCK also phosphorylates and inhibits myosin 
phosphatase (Shimokawa and Takeshita, 2005) permitting 
sustained MLC phosphorylation. As a measure of ROCK 
JEM VOL. 207, April 12, 2010 
Article
883
patient was deficient in KRIT1 protein, and a lesion from 
a familial patient, genotyped as a Ccm2 mutation, lacked 
endothelial CCM2 (Fig. S3). Both the sporadic and the 
familial lesions exhibited dramatic increases in endothelial 
pMLC when compared with control brain tissue (Fig. 4 A). 
The control brain sample showed pMLC in vessel medial 
smooth muscle cell (SMC) layer, as would be expected, because 
coded for by the mutated gene has been observed in lesions 
from heterozygous humans (Pagenstecher et al., 2009) and 
is ascribable to a “second hit” in lesion endothelial cells 
(Akers et al., 2009). Both KRIT1 and CCM2 were detect-
able by immunohistochemistry in control endothelium 
from human anterior temporal lobe tissue removed surgi-
cally for epilepsy. CCM lesion endothelium from a sporadic 
Figure 1. KRIT1 inhibits RhoA and its effector ROCK to reduce MLC phosphorylation and permeability in vitro. (A) HUVECs treated with con-
trol or KRIT1 siRNA were evaluated for RhoA activity. KRIT1-depleted cells had a 3.5-fold increase in GTP-RhoA compared with control, reversible by co-
transfection with WT KRIT1 bearing a knockdown-resistant silent mutation. Error bars are means and SE of n = 6. *, P < 0.001 compared with vector-only 
control siRNA. (B) Total RhoA is shown by immunoblotting, and equal protein content per sample is shown by actin loading. KRIT1 siRNA efficacy is 
shown by immunoprecipitated KRIT1 content. 1, control IP with mouse IgG; 2, control siRNA; 3, KRIT1 siRNA; 4, control siRNA + KRIT1 complementary 
DNA (cDNA); 5, KRIT1 siRNA + KRIT1 cDNA. (C) KRIT1 depletion increased MLC phosphorylation and f-actin stress fiber content. Reconstitution with WT 
KRIT1 prevented pMLC increase and reduced stress fibers. Treatment of KRIT1-depleted cells with ROCK inhibitor H-1152 also prevented MLC phosphory-
lation and stress fiber formation, indicating that ROCK acts downstream of KRIT1. Bar, 50 µm. (D) siRNA efficacy is shown by Western blot probed for 
KRIT1. 1, control IgG IP; 2, control siRNA; 3, KRIT1 siRNA; 4, KRIT1 siRNA+ KRIT1 cDNA; 5, KRIT1 siRNA + H-1152. (E) KRIT1 depletion increases HUVEC 
monolayer permeability in Transwell assays. The increase is reversible by H-1152 treatment, indicating that KRIT1 functions to inhibit ROCK-mediated 
monolayer leak. Error bars are means ± SE of n = 6. *, P < 0.001 compared with control siRNA
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that the RhoA–ROCK pathway is hyperactivated in hu-
man lesion endothelium.
CCM2 depletion increases ROCK activity in vitro
KRIT1 and CCM2 physically associate (Zawistowski 
et al., 2005; Hilder et al., 2007a; Zhang et al., 2007), and 
ROCK signaling is a regulator of vascular SMC contractility 
(Berridge, 2008), but there was little endothelial staining. High 
magnification of a familial lesion vessel demonstrated strong 
pMLC staining in the endothelium (Fig. 4 B). These data 
support the concept that CCM is largely a disorder of endothe-
lial cells (Glading et al., 2007; Boulday et al., 2009) and indicate 
Figure 2. KRIT1 protein haploinsufficiency increases ROCK-mediated vascular leak in vivo. (A) Krit1+/ mice have one-half the amount of KRIT1 
protein in lung and brain as Krit1+/+ mice. 1, control mouse IgG IP; 2, Krit1+/+ lung; 3, Krit1+/+ brain; 4, Krit1+/ lung; 5, Krit1+/ brain lysates. (B) Densitom-
etry of blots in A shows a 50% reduction in KRIT1 in Krit1+/ lysates. Error bars are means ± SE (n = 3). *, P < 0.03 compared with Krit1+/+. (C) Krit1+/ 
mice had significantly greater basal and LPS-induced Evan’s blue dye leak in brain. Error bars are means and SE of n = 6 mice. *, P < 0.01; **, P < 0.04 
compared with vehicle-treated Krit1+/+ mice. Fasudil reduced leak in the Krit1+/ mice. (D) Lungs were collected from animals treated as in C and evalu-
ated for dye extravasation. Basal and LPS-induced lung leak were also reversed by fasudil treatment. Error bars are means ± SE (n = 6). *, P < 0.01; **, P < 
0.03 compared with Krit1+/+. (E) Brain edema (difference in wet weight vs. dry weight) was also tested under the same conditions. Brains were weighed, 
desiccated, and reweighed. Means and SE of data from six animals are shown. Brain edema was increased in Krit1+/ mice and was reduced by fasudil 
treatment. Error bars are means ± SE (n = 6). *, P < 0.01 compared with Krit1+/+. (F) Krit1+/ mice also had increased pulmonary edema, which was dimin-
ished by fasudil treatment. Error bars are means ± SE (n = 6). *, P < 0.01 compared with Krit1+/+.
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Depletion of CCM2 was recently reported to increase 
RhoA-GTP loading in vitro (Crose et al., 2009; Whitehead 
et al., 2009), suggesting that CCM2 deficiency might also 
activate the Rho–ROCK pathway to disrupt endothelial 
homozygous null mutations in either gene result in similar 
lethal vascular and cardiac phenotypes in mice and zebrafish. 
As shown in Fig. 4, we demonstrated that a CCM2-deficient 
human cerebral CCM exhibited increased endothelial pMLC. 
Figure 3. Krit1+/ mouse endothelial cells have increased in vivo and in vitro pMLC and in vitro leak. (A) Endothelial cells were isolated from 
Krit1+/+ and Krit1+/ mouse brain, lung, liver, and kidney as described in Materials and methods, lysed, and Western blotted for immunoprecipitated KRIT1 
protein and for pMLC in whole cell lysate. 1, brain; 2, lung; 3, liver; 4, kidney. Endothelial cells from Krit1+/ mice had similar KRIT1 protein expression in 
all organs but 1/2 the amount seen in Krit1+/+ mice. Endothelial cells from all organs in Krit1+/ mice exhibited increased pMLC content in vitro.  
(B) Isolated pulmonary endothelial cells grown on FN-coated coverslips were also stained for pMLC and f-actin content. Krit1+/ cells exhibited an in-
crease in both. Bar, 50 µm. (C) In vitro permeability assay of isolated pulmonary endothelial cells. Krit1+/ endothelial monolayers were twofold more 
permeable than WT. Permeability was reduced by the ROCK inhibitor H-1152. Error bars are means ± SE (n = 6). *, P < 0.001; **, P < 0.05 compared with 
vehicle-treated Krit1+/+.
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Figure 4. KRIT1 haploinsufficiency increases ROCK activity in human cerebral lesion endothelium. (A) Human CCM cerebral lesions were com-
pared with nonlesion control brain tissue. Slides were processed as described in Materials and methods, stained with anti-pMLC as an index of ROCK acti-
vation, and counterstained with hematoxylin. Control antibody stains are with rabbit IgG. The left and center columns are stained for pMLC, and the right 
column is stained with control antibody. Bars, 500 µm. The CCM lesions are clusters of distended capillaries lacking SMC underlayer. Arrows indicate cav-
ern endothelial cells; asterisks mark lumen of a typical expanded lesion vessel. The control non-CCM brain tissue panel shows an arteriole in cross section, 
exhibiting pMLC in SMC subendothelial layer, but little in endothelial cells (arrow) facing vessel lumen. Sporadic lesion #1 is KRIT1 protein deficient (Fig. 
S3). Familial lesion #2 is CCM2 deficient (Fig. S3) and has equally robust endothelial pMLC staining. (B) Magnified view of familial lesion #2 endothelium.
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layer permeability reversible by ROCK inhibition (Fig. 5 D). 
Thus, like KRIT1, CCM2 acts upstream of ROCK to regu-
late endothelial permeability.
CCM2 haploinsufficiency induces ROCK-mediated vascular leak
To learn whether in vitro CCM2-associated endothelial per-
meability was mirrored by defects in vascular barrier function, 
as was seen with Krit1+/ mice, we also evaluated CCM2 
protein expression in Ccm2+/+ and Ccm2+/ mice. Ccm2+/ 
brain and lung had approximately half the CCM2 protein 
content of WT organs (Fig. 6, A and B). Vascular leak of 
cell–cell junctions. We therefore evaluated CCM2 effects 
on RhoA-ROCK signaling in vitro. siRNA depletion of 
CCM2 increased Rho-GTP levels and pMLC staining in 
HUVEC to a similar extent as KRIT1 depletion and was 
reversed by coexpression of siRNA-resistant CCM2 (Fig. 5, 
A and C). Total RhoA expression was equivalent in all 
conditions (Fig. 5 B). Similar effects were observed in 
staining for a second ROCK substrate, phospho-MYPT1 
(Fig. S1). The effects of CCM2 depletion were reversed 
by treatment with ROCK inhibitors H-1152 or Y27632. 
Finally, CCM2 depletion caused increased HUVEC mono-
Figure 5. CCM2 depletion increases RhoA and ROCK activity in vitro. (A) HUVECs were treated with CCM2 or control siRNA, with or without WT 
CCM2 bearing a silent mutation resistant to knockdown. Depletion of CCM2 produced a four- to sixfold increase in GTP-RhoA, reversible by cotransfection 
with WT CCM2. Error bars are means ± SE (n = 6). *, P < 0.001 compared with control siRNA. (B) Total RhoA is equal in all treatments. Equal sample protein is 
shown by GAPDH. CCM2 knockdown and reconstitution efficacy are shown by immunoprecipitated CCM2. 1, vector + control siRNA; 2, vector + CCM2 siRNA; 
3, control siRNA + WT CCM2 cDNA; 4, CCM2 siRNA + WT CCM2 cDNA; 5, control rabbit IgG IP. (C) CCM2 depletion by siRNA increases pMLC and stress fiber 
content of HUVEC, reversible by treatment with ROCK inhibitor H-1152. Bar, 50 µm. (D) As previously seen with KRIT1, CCM2 presence is required for suppres-
sion of ROCK-mediated monolayer permeability. Error bars are means ± SE (n = 4). *, P < 0.001 compared with vehicle-treated control siRNA.
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protein, with Ccm2+/ mice expressing one-half as much 
as Ccm2+/+ mice (Fig. 7 A). Like the Krit1+/ mice, iso-
lated endothelial cells from all organs of Ccm2+/ mice 
showed increased pMLC content (Fig. 7, A and B) and in-
creased monolayer permeability (Fig. 7 C). Thus, CCM2 
deficiency phenocopies effects of KRIT1 deficiency on 
dysregulation of Rho-ROCK signaling and resulting vas-
cular barrier dysfunction.
Evan’s blue dye was increased in brain and lung of Ccm2+/ 
animals compared with WT littermates, both in basal condi-
tions and in response to LPS challenge (Fig. 6, C and D). 
Organ edema was proportionately increased as well (Fig. 6, E 
and F). Increased permeability and organ edema were reversed 
by treatment with fasudil (Fig. 6, C–F). As was seen with 
Krit+/1 mice, isolated mouse brain, lung, liver, and kidney 
endothelial cells expressed equivalent amounts of CCM2 
Figure 6. CCM2 protein haploinsufficiency increases ROCK-mediated vascular leak. (A) Lung and brain lysates of Ccm2+/+ and Ccm2+/ mice evaluated 
for CCM2 protein content show a 50% protein reduction in Ccm2+/. 1, control mouse IgG IP; 2, Ccm2+/+ lung; 3, Ccm2+/+ brain; 4, Ccm2+/ lung; 5, Ccm2+/ 
brain lysates. (B) Densitometry shows one-half CCM2 protein expression in heterozygous mouse lung and brain compared with WT. Error bars are means ± SE  
(n = 3). *, P < 0.01 compared with same organ of Ccm2+/+ mouse. (C) Ccm2+/+ and Ccm2+/ mice were evaluated for basal and LPS-induced cerebral vascular leak 
as described in Fig. 2. Ccm2+/ mice had significantly greater basal and induced leaks, reversible by ROCK inhibition with fasudil. Error bars are means ± SE (n = 6). 
*, P < 0.01; **, P < 0.03 compared with vehicle-treated Ccm2+/+. (D) Similarly, pulmonary vascular leak was increased in Ccm2+/ mice and was also reduced by 
fasudil. Error bars are means ± SE (n = 6). *, P <0.01; **, P < 0.04 compared with vehicle-treated Ccm2+/+. (E and F). Brain and lung edema in Ccm2+/ mice were 
increased, reversible by fasudil treatment. Error bars are means ± SE (n = 6). *, P < 0.01; **, P < 0.02 compared with vehicle-treated Ccm2+/+ for both panels.
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these proteins is important in their biological functions. In this 
paper, we have shown that CCM2 and KRIT1 both influ-
ence vascular barrier function by inhibiting activity of RhoA 
and its effector ROCK. To test whether physical interaction 
of KRIT1 and CCM2 modulates RhoA-ROCK signaling, 
Physical interaction of KRIT1 with CCM2 is required  
for suppression of ROCK-mediated permeability
CCM2 mutations that inhibit its association with KRIT1 are 
linked to CCM disease in humans (Plummer et al., 2006; 
Liquori et al., 2007), suggesting that physical interaction of 
Figure 7. Ccm2+/ mouse endothelial cells exhibit increased pMLC in vivo and in vitro. (A) Endothelial cells isolated from Ccm2+/+ and Ccm2+/ 
mouse brain, lung, liver, and kidney were lysed and probed for CCM2 protein and pMLC content. 1, brain; 2, lung; 3, liver; 4, kidney. Endothelial cells from 
all organs have equivalent expression of CCM2 protein; however, Ccm2+/ endothelial cells express 50% as much CCM2 as those from Ccm2+/+ mice. 
Ccm2+/ mouse endothelial cells exhibited increased pMLC content compared with WT. (B) Pulmonary endothelial cells were probed for pMLC and actin 
structure in vitro. Increased MLC phosphorylation and stress fiber content are seen in Ccm2+/ cells. Bar, 50 µm. (C) Ccm2+/ endothelial cells exhibit in-
creased monolayer permeability reversible by treatment with ROCK inhibitor H-1152. Error bars are means ± SE (n = 6). *, P < 0.001; **, P < 0.05 compared 
with vehicle-treated Ccm2+/+ cells.
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Figure 8. Physical interaction of CCM2 and KRIT1 is required for their endothelial junctional localization and for inhibition of RhoA→
ROCK-mediated permeability. HUVECs were transfected with siRNA to deplete endogenous CCM2 and reconstituted with either WT CCM2 or CCM2-
F217A, a mutation which abrogates CCM2 binding to KRIT1. Both WT CCM2 and CCM2-F217A constructs bear silent mutations conferring resistance to 
CCM2 siRNA. (A) Endogenous CCM2 and KRIT1 protein are localized to HUVEC endothelial cell–cell junctions in cells treated with control siRNA. CCM2 
JEM VOL. 207, April 12, 2010 
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depletion by siRNA causes KRIT1 loss from junctions. Reconstitution of depleted endogenous CCM2 by transfection with CCM2-F217A does not restore 
junctional localization either to the mutant CCM2 or to endogenous KRIT1. Reexpressed WT CCM2 is junctional and permits endogenous KRIT1 junctional 
localization. (B) CCM2-F217A reconstitution of endogenous CCM2 depletion fails to suppress RhoA activity, whereas reconstitution with WT CCM2 limits 
RhoA activity. Error bars are means ± SE (n = 4). *, P < 0.01 compared with vector-treated control siRNA. (C) Transfection and knockdown efficacy for  
A and B is shown by Western blotting for CCM2 and total RhoA content. Equal loading is shown by staining for GAPDH. 1, vector; 2, vector + CCM2 
siRNA; 3, CCM2 cDNA; 4, CCM2 cDNA+ CCM2 siRNA; 5, CCM2-F217A cDNA; 6, CCM2-F217A cDNA + CCM2 siRNA; 7, control rabbit IgG IP. (D) CCM2 de-
pletion causes increased pMLC and actin stress fiber content, reversible by reconstitution with WT CCM2 but not by CCM2-F217A, indicating a require-
ment for CCM2-KRIT1 physical interaction for suppressing ROCK activity. Bar, 50 µm. (E) CCM2 depletion-induced hyperpermeability is not reversible by 
CCM2-F217A reconstitution. Error bars are means ± SE (n = 6). *, P < 0.001 compared with control siRNA.
 
we first asked whether CCM2 is an endothelial junctional 
protein because previous studies reached divergent conclu-
sions about CCM2 localization (Petit et al., 2006; Seker et al., 
2006; Kleaveland et al., 2009), possibly as a result of staining 
of overexpressed recombinant proteins or differences in stain-
ing technique. Anti-CCM2 antibody stained endogenous 
CCM2 in HUVEC cell–cell junctions, which is consistent 
with its physical association with KRIT1 (Fig. 8 A). Further-
more, CCM2 depletion led to loss of KRIT1 from the cell–
cell junctions. We used CCM2 siRNA to deplete HUVEC 
of endogenous CCM2 and then reconstituted with CCM2-
F217A, a mutation which renders CCM2 unable to physically 
interact with KRIT1 (Zawistowski et al., 2005; Hilder et al., 
2007a,b). CCM2 reconstitutions were equivalent in all trans-
fections (Fig. 8 C). CCM2-F217A did not suppress RhoA 
activity (Fig. 8 B), nor did it restore the junctional localization 
of KRIT1 (Fig. 8 A). To evaluate further effects on ROCK 
activity and function, we probed CCM2 siRNA-depleted 
HUVEC for pMLC, actin stress fibers, and measured mono-
layer permeability. Reconstitution with CCM2-F217A failed 
to prevent MLC phosphorylation increase and stress fiber 
accumulation (Fig. 8 D), nor did it prevent increased permea-
bility (Fig. 8 E). These data indicate that physical interaction 
of KRIT1 and CCM2 protein is required for KRIT1 junc-
tional localization and for suppression of RhoA and ROCK 
activity to maintain vascular barrier function.
DISCUSSION
KRIT1 and CCM2 have been shown separately to regulate 
vasculogenesis (Whitehead et al., 2004, 2009; Kleaveland 
et al., 2009). Our earlier work identified KRIT1 as a Rap1 
effector that is localized to endothelial cell–cell junctions in 
vitro and is required for junctional stability to limit mono-
layer permeability (Glading et al., 2007). In this paper, we 
establish a signaling pathway whereby KRIT1 regulates 
vascular permeability. KRIT1 interacts with CCM2 to stabi-
lize endothelial cell–cell junctions, and they conjointly sup-
press RhoA activity and, thus, activation of the RhoA effector 
ROCK. We show that hemizygous deficiency of either 
KRIT1 or CCM2 leads to ROCK-mediated vascular leak 
in mice, suggesting much more widespread consequences of 
hemizygous deficiency of these proteins than previously 
appreciated. This vascular leak is reversible by treatment with a 
ROCK inhibitor, fasudil, an agent in clinical use. Further-
more, we find increased phosphorylation of the ROCK 
substrate MLC in the endothelium of human CCM lesions 
associated with lack of either KRIT1 or CCM2. Thus, we 
define a mechanism by which KRIT1 interaction with CCM2 
stabilizes endothelial cell junctions, we report that haploinsuf-
ficiency of either of these proteins leads to vascular leak in 
mice and dysregulated cerebral endothelial ROCK signal-
ing in humans, and we identify fasudil as a potential therapy 
for CCM disease.
These studies indicate that a signaling module of KRIT1 
and CCM2 acts as a negative regulator of RhoA, thereby 
limiting ROCK activity downstream. We show in this paper 
that CCM2, like KRIT1, localizes to endothelial junctions, 
and its direct physical interaction with KRIT1 is required for 
maintenance of endothelial junctional stability by suppressing 
ROCK activity. Binding of KRIT1 to CCM2 leads to 
KRIT1 transport out of the nucleus (Zawistowski et al., 
2005). Once in the cytosol, KRIT1 can interact with junc-
tional components, such as -catenin (Glading et al., 2007) 
or Heg1 (Kleaveland et al., 2009), to recruit it to cell–cell 
junctions. Depletion of either KRIT1 or CCM2 by in vitro 
siRNA increased RhoA-GTP, confirming previous results 
showing that depletion of CCM2 leads to increased RhoA 
activity (Crose et al., 2009; Whitehead et al., 2009). 
Importantly, we show that reconstitution with WT CCM2, 
but not with a CCM2 mutant unable to interact with 
KRIT1, reverses the effects of CCM2 depletion, emphasiz-
ing that KRIT1 and CCM2 act as a complex. CCM2 inter-
action enables KRIT1 translocation from nucleus to plasma 
membrane in nonendothelial cells (Zawistowski et al., 
2005), and we find that depletion of CCM2 leads to mislo-
calization of KRIT1 from endothelial cell–cell junctions. 
Thus, it is likely that the two proteins interact for sustained 
localization at junctional membranes, where they could 
regulate RhoA activity by influencing Rho GEFs or GAPs. 
Recently, Crose et al. (2009) found that CCM2 interacts 
with Smurf1, an E3 ubiquitin ligase, leading to reduced 
RhoA expression in an endothelial cell line; however, we 
saw no differences in total RhoA as a consequence of CCM2 
or KRIT1 depletion in primary endothelial cells. Alterna-
tively, CCM2 is a scaffold for MEKK3, p38 MAPK, and 
Rac1 (Uhlik et al., 2003; Fong et al., 2007; Hilder et al., 
2007b). Rac1 activity counters RhoA-mediated stress fiber 
formation and stabilizes microvascular barrier function, 
although Rac1 can itself also mediate barrier disruption 
(Wójciak-Stothard et al., 2001, 2005; van Wetering et al., 2002; 
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tion. ROCK hyperactivation in embryogenesis could con-
tribute to the developmental aortic obstruction seen in both 
zebrafish and mice (Whitehead et al., 2004; Mably et al., 
2006; Malone et al., 2007; Hogan et al., 2008) by producing 
localized sustained contraction of vascular cells. Alternatively, 
there may be other effects of KRIT1 deficit, for example, 
KRIT1 can enter the nucleus; hence, future studies will be 
needed to ascertain the hierarchy of the complex events that 
lead to CCM lesion formation. That said, our data point 
to ROCK signaling as a key player.
Human CCM lesions manifest a robust oligoclonal anti-
gen-driven immune response (Shi et al., 2007, 2009). Radia-
tion exposure can also trigger de novo development of CCM 
lesions (Jain et al., 2005; Nyáry et al., 2007). The majority of 
human lesions occur sporadically, in association with preex-
isting developmental venous anomalies or capillary telangiec-
tasia (Gault et al., 2004, 2006; Al-Shahi Salman et al., 2008). 
These conditions may contribute to a background of in-
creased vascular permeability, as seen in the heterozygous 
genetic state, favoring CCM lesion genesis. Our results dem-
onstrate that sporadic human CCMs display excess ROCK 
activity to the same extent as familial heterozygous CCM2 
lesions. ROCK-mediated low level constitutive cerebral 
vessel hyperpermeability is potentially a critical factor predis-
posing to both types of lesion genesis.
Long-term treatment of CCM patients with fasudil could 
prove beneficial in preventing hemorrhagic stroke and deter-
ring formation of new lesions by strengthening cerebral 
microvascular endothelial stability. Fasudil inhibition of 
ROCK acts through competitive binding with ATP for a 
catalytic site. It also inhibits Ca2+ sensitization of myosin 
phosphorylation (Olson, 2008). Fasudil is currently used for 
cerebral vasospasm treatment in Japan and is well tolerated in 
man. Moreover, it is currently undergoing human trials in 
the United States for treatment of pulmonary hypertension 
and other diseases (Olson, 2008). Our studies suggest that 
fasudil could also prove beneficial in acute situations of path-
ological vascular leak (e.g., sepsis) as well as CCM. Support 
for this idea also comes from recent studies showing that a 
ROCK inhibitor can ameliorate thrombin or TNF-mediated 
endothelial permeability in vitro (Mong and Wang, 2009; 
Satoh et al., 2010). In light of increased leak response of 
Krit1+/ and Ccm2+/ mice to LPS in this experiment, human 
CCM patients could have heightened susceptibility to non-
cerebral vascular pathologies, in which case fasudil could pro-
vide additional therapeutic benefit.
MATERIALS AND METHODS
Cell culture. HUVEC (Cambrex) and primary mouse pulmonary endo-
thelial cells were cultured in EGM2 medium (Cambrex), 10% fetal bovine 
serum, and 1% penicillin/streptomycin (Invitrogen).
siRNA and cDNA. siRNA against human KRIT1 (Applied Biosystems) 
was previously described (Glading et al., 2007). siRNA against human 
CCM2 was obtained from Thermo Fisher Scientific. Negative control 
siRNA having no known human, mouse, or rat gene targets was obtained 
from Thermo Fisher Scientific. cDNA for hemagglutinin-tagged full length 
KRIT1 was previously described (Glading et al., 2007). pRK5-CCM2 
Stockton et al., 2004, 2007; Gavard and Gutkind, 2006; 
Tan et al., 2008).
RhoA has multiple effectors but its regulation of vas-
cular contractility is largely accomplished through ROCK. 
ROCK-mediated induction of endothelial permeability 
occurs in response to a variety of cytokines and growth 
factors (Loirand et al., 2006); hence, KRIT1 and its associ-
ated proteins may serve as a physiological brake on vascular 
leak induced by many agonists. Krit1+/ and Ccm2+/ mice 
expressed half-normal amounts of their gene products 
accompanied by defective vascular barrier function in both 
brain and lung. Heterozygosity-associated vascular leak was 
reversible by fasudil treatment, demonstrating that the in 
vitro KRIT1/CCM2→RhoA→ROCK signaling pathway is 
also operative in preventing vascular leak in vivo. It is possi-
ble that a KRIT1/CCM2 deficit-associated leak may con-
tribute to CCM lesion formation. Although Krit1+/ and 
Ccm2+/ mice mimic the genetic status of human CCM 
patients, heterozygous mice generally lack CCMs unless they 
are sensitized by a lack of p53 (Plummer et al., 2004). This 
lack of lesion formation may be a result of variability in pene-
trance, as with humans (Plummer et al., 2004; Gianfrancesco 
et al., 2007; Liquori et al., 2007), or of the shorter lifespan 
of mice. Our findings raise the possibility that another conse-
quence of Krit1 or Ccm2 mutations may be a generalized 
defect in endothelial barrier function.
ROCK1 and 2 are serine/threonine kinases, which con-
tribute to stress fiber formation by inactivating myosin phos-
phatase and by phosphorylating MLC. pMLC is a regulator 
of endothelial and SMC contractility, thus playing a central 
role in vascular tone and function (van Hinsbergh and van 
Nieuw Amerongen, 2002; Sun et al., 2006). ROCK also 
activates Lim kinase to inhibit cofilin, which prevents actin 
depolymerization, and it further increases contractility by 
directly phosphorylating MLC. Increased contractility can 
disrupt cell–cell adhesion and contribute to increased vascular 
permeability (Dudek and Garcia, 2001; Rolfe et al., 2005). 
ROCK also phosphorylates claudins in tight junctions to 
regulate permeability of the blood-brain barrier, which is 
largely composed of tight junctions (Yamamoto et al., 2008). 
The effect of ROCK on claudins may prove to be of particu-
lar interest in CCM disease, wherein lesions are predomi-
nantly cerebral, are known to have defective junctional 
contacts, and are known to leak (Clatterbuck et al., 2001).
Increasing evidence shows that CCM is a largely endothe-
lial disease (Glading et al., 2007; Shenkar et al., 2008a,b; 
Pagenstecher et al., 2009). We herein related human CCM 
disease to a ROCK-mediated vascular defect by evaluating 
human CCM lesions for pMLC. pMLC was present in strik-
ing amounts in endothelium of both sporadic and familial 
human lesions associated with either KRIT1 or CCM2 
deficiency. Thus, it is likely that the complete lack of KRIT1 
or CCM2 in CCM lesion endothelium leads to excessive 
activation of RhoA-ROCK signaling, resulting in local 
hyperpermeability. Our data also raise the possibility that 
ROCK signaling contributes to other aspects of lesion forma-
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incubated for 48 h at 37°C in 5% CO2 to full confluence. Medium was 
replaced with phenol-free DME with 1% serum. In some assays, cells were 
treated with vehicle or 3 µM ROCK inhibitor H-1152 for 30 min. In con-
trol experiments, an alternate ROCK inhibitor, Y27632, was used at 1 µM. 
50 µl of phenol-free DME containing 1.5 µg/ml of horseradish peroxidase 
(Sigma-Aldrich) were added to all filter upper wells for 60 min. In some 
experiments, 1.5 µg/ml FITC-dextran (44 kD; Sigma-Aldrich) replaced 
HRP as a label. Filters were removed from outer wells, fixed in 3.5% form-
aldehyde, and stained with 0.25% Coomassie blue for microscopy to recon-
firm the integrity of cell monolayers.
HRP content of lower chamber medium was measured using a micro-
plate peroxidase colorimetric assay as previously described (Glading et al., 
2007). A490 was acquired and raw absorbance values were normalized as a 
percentage of control untransfected (vehicle only) cell sample absorbance. 
For experiments using the FITC-dextran label, 100 µl of lower chamber 
medium/well in triplicates per sample was analyzed by 96-well microplate 
fluorimetry. Data from at least three experiments were pooled and analyzed 
for statistical significance using analysis of variance (ANOVA) with Sigma-
Stat software (SPSS). Graph bars indicate means and SE of pooled data. n- and 
p-values are shown in the figure legends.
Pulmonary endothelial cell isolation. Mouse primary vascular endothe-
lial cells were isolated from tissues by sequential CD45-negative and CD31-
positive immunomagnetic bead selection. Animals were perfused with HBSS 
containing dispase and 0.2% collagenase. Brains, lungs, livers, and kidneys 
were removed, minced, and further digested in dispase/0.2% collagenase 
(Sigma-Aldrich). Organs from the same genotype were pooled for collec-
tion. A single-cell suspension was prepared by passing digested organs 
through a 70-µm cell strainer (BD). Cells were incubated with biotinylated 
rat anti–mouse CD45, washed, and then incubated with anti-biotin micro-
beads (Miltenyi Biotec). Cells were washed and placed in a microtube in a 
magnet unit (Invitrogen) to isolate CD45+ cells. CD45-negative cells were 
collected and labeled with rat anti–mouse CD31 (Invitrogen). Cells were 
washed, and then anti–rat IgG-coated magnetic beads were added and 
CD31+ cells were isolated by magnet. Endothelial cell identity was con-
firmed by FACS for VE-cadherin (Fig. S2). Cells were grown on FN-coated 
coverslips, cultured in EBM2 medium, or lysed for Western blotting.
Rho activity assay. Cells transfected as described in the Transfection 
section were plated in FN-coated 60-mm culture dishes concurrent with 
permeability and immunofluorescence assays and grown for 48 h. Cells were 
washed with ice-cold HBSS, and then plates were flash frozen on dry ice and 
stored at 70°C. Frozen cells on plates were scraped with assay lysis buffer 
(Cytoskeleton, Inc.) and cell lysates clarified by centrifugation for 10 min at 
14,000 g at 4°C. Protein content was measured using a DC Protein Assay kit 
(Bio-Rad Laboratories). Samples containing equal amounts of protein were 
subjected to either colorimetric or luminescence quantitative microplate 
enzymeimmunoassay for GTP-bound RhoA according to the manufactur-
er’s direction (Cytoskeleton, Inc). For colorimetric assays, mean sample 
absorbance at 690 nm, and for luminescent assays, mean sample light units, 
were normalized to control samples and statistically analyzed by ANOVA as 
indicated in the figure legends.
Mice. Krit1+/ and Ccm2+/ mice backcrossed onto C57BL/6J background 
have been previously described (Whitehead et al., 2004; Plummer et al., 
2006; provided by D. Marchuk, Duke University, Durham, NC). All 
experiments performed using mice were in accord with animal proce-
dure protocols approved by the University of California, San Diego Institu-
tional Animal Care and Use Committee.
Evan’s blue dye in vivo extravasation and edema assays. Krit1+/ and 
Ccm2+/ mice were age-matched to WT littermates. Evan’s blue (EB) 
extravasation from blood into interstitial tissue was evaluated as previously 
described (Reutershan et al., 2007; Stockton et al., 2007). Organs were eval-
uated for edema as wet weight percentage of total organ weight, as a secondary 
encoding FLAG-tagged WT human CCM2 has been previously described 
(Zawistowski et al., 2005). siRNA-resistant silent mutations were con-
structed for knockdown reconstitution studies. Additional silent mutations in 
the coding sequence created a vector encoding siRNA-resistant CCM2-
F217A, a mutant unable to bind KRIT1 (Zawistowski et al., 2005).
Transfection. HUVEC were transfected using a Nucleofector (Lonza) as 
previously described (Glading et al., 2007). In brief, 0.5 × 106 cells/transfec-
tion were suspended in HUVEC Solution (VPB-1002; Lonza) with 2.5 µg 
siRNA, with or without 1.5 µg DNA, nucleoporated using program M-003 
or A-034, and then plated on fibronectin (FN)-coated culture plates 
(Falcon), glass coverslips (Corning), or Transwell 3-µm- polyester filters 
(Corning) as indicated.
Immunoprecipitation and Western blotting. Cells were scraped in lysis 
buffer (50 mM Tris, 150 mM NaCl, 0.5% NP-40, and 5 mM MgCl2, plus 
protease-phosphatase inhibitor cocktails; Sigma-Aldrich). Lysates were centri-
fuged at 14,000 rpm for 10 min, and protein concentrations were determined 
by BCA assay (Thermo Fisher Scientific). 500 µg of protein was precleared 
with 25 µl of 50% protein G–Sepharose beads (GE Healthcare), and then 
supernatants were incubated with 2–5 µg of immunoprecipitating antibody at 
4°C with continuous rocking for 2 h. 25 µl of protein G–Sepharose beads 
were added and incubated overnight at 4°C with continuous rocking. Pellets 
were centrifuged at 8,000 g for 2 min and washed three times with lysis buffer. 
Protein was solubilized by heating at 95°C for 5 min in 20 µl SDS-PAGE 
sample buffer and then fractionated on 4–20% SDS-PAGE. Protein was trans-
ferred to nitrocellulose membranes and detected by immunoblotting.
Reagents. Monoclonal anti-KRIT1 (15B2) and polyclonal anti-KRIT1 
(6832) antibodies were previously described (Glading et al., 2007). Anti-
KRIT1 15B2 was used for immunoprecipitation and immunofluorescence 
at 1:1,000. Rabbit anti-KRIT1 6832 serum was used for immunoblotting at 
1:1,000. Anti-GAPDH (Santa Cruz Biotechnology, Inc.) was used at 
1:2,000. Nonimmune mouse and rabbit IgG were obtained from Santa Cruz 
Biotechnology, Inc. Rabbit and mouse polyclonal anti-CCM2 (Abnova) 
were used for immunoblotting and immunostaining at 1:1,000 and 1:500, 
respectively. Anti–phospho [Thr180/Ser19]-MLC antibodies (Cell Signal-
ing Technology) were used for immunoblotting at 1:1,000, immunostaining 
at 1:500, and immunohistochemistry at 1:250. Rabbit anti-MYPT1 and goat 
anti–phospho [Thr853]-MYPT1 were obtained from Santa Cruz Biotech-
nology, Inc. Alexa-conjugated anti-IgG and Alexa-conjugated phalloidin 
were obtained from Invitrogen. Goat anti–rabbit IgG-biotin antibody was 
obtained from Vector Laboratories. ROCK inhibitors H-1152, Y27632, and 
fasudil (5-Isoquinolinesulfonyl homopiperazine, 2HCl) were obtained from 
EMD. Evans blue dye and all other reagents were obtained from Sigma- 
Aldrich unless otherwise indicated.
Immunofluorescence. Cells grown to 80% percent confluence on 
FN-coated glass coverslips were fixed with 3.7% formaldehyde for 30 min, 
permeabilized for 10 min with 0.15% Triton X-100, and blocked for 1 h 
with 10% normal goat serum (Invitrogen) in TBS-Tween (TBST). Antibodies 
diluted in TBS were added to coverslips and incubated overnight in a 
humidified chamber. Coverslips were washed with TBST and then incu-
bated with indicated Alexa-labeled anti-IgG (Invitrogen) at 1:1,000 over-
night at 4°C. Coverslips were washed in TBST and then mounted using 
Prolong Gold (Invitrogen). Imaging was performed by a microscope (LR23; 
Leica) with a charge-coupled device camera (model 2.2.1; Diagnostic Instru-
ments, Inc.) or a confocal microscopy system (TCS SP2 AOBS with DMRE 
microscope and HCX PL APO 63×/1.32 oil objective; Leica). Images were 
acquired for each experiment using the same gamma settings for all samples 
and processed using Photoshop II software (Adobe).
Endothelial in vitro permeability assay. HUVEC or primary mouse 
endothelial cells were nucleoporated with indicated siRNA and/or cDNA, 
plated into 3-µm pore polyester FN-coated Transwell filters (Corning), and 
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lesion expression of KRIT1 and CCM2 protein. Online supplemental mate-
rial is available at http://www.jem.org/cgi/content/full/jem.20091258.
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